Holen Sie sich die Stockscreener-App
0.8391
2.66%
-0.0235
Schlusskurs vom Vortag:
$0.8625
Offen:
$0.88
24-Stunden-Volumen:
143.08K
Relative Volume:
0.28
Marktkapitalisierung:
$72.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-50.21M
KGV:
-0.4404
EPS:
-1.9053
Netto-Cashflow:
$-16.61M
1W Leistung:
+8.36%
1M Leistung:
+2.70%
6M Leistung:
-30.03%
1J Leistung:
-35.91%
1-Tages-Spanne:
$0.832
$0.88
1-Wochen-Bereich:
$0.79
$0.9598
52-Wochen-Spanne:
$0.694
$2.18
Rein Therapeutics Inc Stock (RNTX) Company Profile
Firmenname
Rein Therapeutics Inc
Sektor
Branche
Telefon
(737) 802-1989
Adresse
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
0.8396 | 74.41M | 0 | -50.21M | -16.61M | -1.9053 |
VRTX
Vertex Pharmaceuticals Inc
|
521.74 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.21 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.49 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.88 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-07-24 | Eingeleitet | BofA/Merrill | Buy |
| 2017-07-24 | Eingeleitet | Jefferies | Buy |
| 2017-07-24 | Eingeleitet | William Blair | Outperform |
Rein Therapeutics Inc Aktie (RNTX) Neueste Nachrichten
Rein Therapeutics Inc (NASDAQ: RNTX) Stock Price, News & Analysis - Kalkine
Rein Therapeutics Receives Nasdaq Delisting Notice Over Bid Price - TipRanks
RNTX: LTI-03 advances in Phase 2 IPF trials after promising safety and biomarker results - TradingView
Rein Therapeutics Highlights LTI-03 Progress in IPF - TipRanks
Rein Therapeutics publishes LTI-03 presentation; Phase 1b biomarker signals and Phase 2 RENEW now enrolling - TradingView
Inhaled IPF drug from Rein Therapeutics (NASDAQ: RNTX) shows early safety data - Stock Titan
A study of an inhaled treatment for lung scarring will be presented Sept. 8 in Barcelona. - Stock Titan
Rein Therapeutics to Present at Upcoming September Investor Conferences - Yahoo Finance
Here's Why You Should Add RNTX Stock to Your Portfolio Now - The Globe and Mail
Rein Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Rein (RNTX) Quarter in Focus: The Available Earnings Metric Delivers a Beat on the Day; Post-Report: Shares Move 0.88% Higher in the Current UpdateGuidance Accuracy Score - vinanet.vn
Rein Therapeutics receives FDA fast track for IPF drug LTI-03 - Investing.com Nigeria
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - The Manila Times
Rein Therapeutics Receives FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - Quiver Quantitative
Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis - TradingView
FDA grants Fast Track designation to inhaled treatment for lung disease with 3-to-5-year median survival - Stock Titan
Equities Analysts Set Expectations for RNTX FY2026 Earnings - MarketBeat
What is HC Wainwright's Estimate for RNTX FY2030 Earnings? - MarketBeat
RNTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Rein Therapeutics (NASDAQ:RNTX) Given "Buy" Rating at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Buy on Rein Therapeutics stock By Investing.com - Investing.com Canada
RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates as Stock Climbs 2.35%Tech Earnings Analysis - Vinanet
Rein Therapeutics (NASDAQ:RNTX) Announces Earnings Results - MarketBeat
Rein Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Rein Therapeutics (RNTX) Holds at $0.79 as Range-Bound Trading PersistsVWAP Bounce - Vinanet
Rein Therapeutics Raises $44.3 Million in Public Offering - Minichart
Rein Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Rein Therapeutics Surpasses 25% Enrollment in Phase 2 RENEW Trial of LTI-03 for IPF, Completes $57.5 Million Public Offering - Quiver Quantitative
Press Release: Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Rein Therapeutics 2Q 2026: Revenue $0 Net loss $6.4M, EPS $(0.10) — 10-Q Summary - TradingView
RNTX: Q2 net loss narrowed, liquidity strengthened, and Phase 2 LTI-03 trial remains on track - TradingView
Rein Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Rein Therapeutics Inc. (NASDAQ:RNTX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
RNTX Q1 2026 Earnings: Narrowed Per-Share Loss Beats Consensus by Nearly 62%Financial Health Score - vinanet.vn
RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Improved Capital DisciplineOne-Time Loss Impact - vinanet.vn
Rein Therapeutics (NASDAQ:RNTX) Shares Down 2.9%Here's Why - MarketBeat
Rein Therapeutics Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Rein Therapeutics Inc (RNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Certain Stock Options of Rein Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 9-AUG-2026. - marketscreener.com
Certain Warrants of Rein Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 9-AUG-2026. - marketscreener.com
Rein Therapeutics Inc (RNTX) Stock News Today - TradingKey
RNTX PE Ratio & Valuation, Is RNTX Overvalued - Intellectia AI
Rein Therapeutics’ LTI-03 study published in Nature Communications - Investing.com
Rein Therapeutics’ LTI-03 study published in Nature Communications By Investing.com - Investing.com Canada
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications - Yahoo Finance
Rein Therapeutics (RNTX) Dips 2.76% to $0.74, Pressing Against Key SupportSuperTrend - dars.gov.et
Rein Therapeutics Inc (RNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rein Therapeutics Inc (RNTX) Cash Flow - TradingKey
Rein Therapeutics Inc (RNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rein Therapeutics Inc (RNTX) Income Statement - TradingKey
Finanzdaten der Rein Therapeutics Inc-Aktie (RNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rein Therapeutics Inc-Aktie (RNTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| VON RICKENBACH JOSEF H | Director |
May 22 '26 |
Buy |
1.05 |
15,950 |
16,708 |
34,824 |
| VON RICKENBACH JOSEF H | Director |
May 27 '26 |
Buy |
1.07 |
4,500 |
4,819 |
62,514 |
| VON RICKENBACH JOSEF H | Director |
May 21 '26 |
Buy |
1.04 |
3,420 |
3,564 |
18,874 |
| WINDSOR JAMES BRIAN | See Remarks |
Apr 30 '26 |
Buy |
1.00 |
25,000 |
25,000 |
27,046 |
| Voss Capital, LP | 10% Owner |
Nov 14 '25 |
Buy |
1.22 |
104,183 |
127,593 |
926,441 |
| Voss Capital, LP | 10% Owner |
Oct 28 '25 |
Buy |
1.39 |
178,392 |
247,965 |
500,000 |
| Voss Capital, LP | 10% Owner |
Oct 27 '25 |
Buy |
1.37 |
97,482 |
133,544 |
822,258 |
| Voss Capital, LP | 10% Owner |
Oct 24 '25 |
Buy |
1.39 |
30,176 |
41,957 |
729,616 |
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):